Personalised medicine for psoriasis: A real possibility ahead

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 8, 2010, Pages 588-590

  Thng, Tien Guan ^a   Lim, Kar Seng ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; METHOTREXATE; USTEKINUMAB; VASCULOTROPIN; VITAMIN D RECEPTOR;

DISEASE COURSE; DRUG RESPONSE; DRUG SCREENING; EDITORIAL; GENE TARGETING; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; MOLECULARLY TARGETED THERAPY; PHARMACOGENETICS; PSORIASIS; PSORIATIC ARTHRITIS; TH17 CELL; TOXICITY TESTING;

EID: 77957367180     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Editorial

References (19)

1. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006:78:827-51.
2. Capon F, Helms C, Veal CD, Tillman D, Burden AD, Barker JN, et al. Genetic analysis of PSORS2 markers in a UK dataset supports the association between RAPTOR SNPs and familial psoriasis. J Med Genet 2004:41:459-60.
3. Foerster J, Nolte I, Schweiger S, Ehlert C, Bruinenberg M, Spaar K, et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J Invest Dermatol 2004:122:61-4.
4. Sun C, Mathur P, Dupuis J, Tizard R, Ticho B, Crowell T, et al. Peptidoglycan recognition proteins Pglyrp3 and Pglyrp4 are encoded from the epidermal differentiation complex and are candidate genes for the Psors4 locus on chromosome 1q21. Hum Genet 2006:119:113-25.
5. Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Cantone K, et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 2002:79:305-14.
6. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007:80:273-90.
7. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985:13:450-6.
8. Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, Jónsson HH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006:126:740-5.
9. Young HS, Summers AM, Bhushan M, Brenchley PEC, Griffiths CEM. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004:122:209-15.
10. Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, Sanchez del Río J, Rodriguez Pérez A, et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum 1999;42:1010-6.
11. González S, Brautbar C, Martínez-Borra J, López-Vazquez A, Segal R, Blanco-Gelaz MA, et al. Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population. Human Immunology 2001;62:632-8.
12. González S, Martínez-Borra J, López-Vázquez A, García-Fernández S, Torre-Alonso JC, López-Larrea C, et al. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol 2002;29:973-8.
13. Korendowych E, McHugh N. Genetic Factors in Psoriatic Arthritis. Curr Rheumatol Rep 2005;7:306-12.
14. Halsall JA, Osborne JE, Pringle JH, Hutchinson PE. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics 2005:15:349-55.
15. Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004:19:511-9.
16. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001:120:1347-55.
17. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003:48:1849-52.
18. Schotte H, Schlüter B, Drynda S, Willeke P, Tidow N, Assmann G, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005:64:575-81.
19. Carson PE, Flanagan CL, Ickes CE, Alvong AS. Enzymatic deficiency in primaquine sensitive erythrocytes. Science 1956:124:484-5.